Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

70.91USD
10:46am EST
Price Change (% chg)

$-1.49 (-2.06%)
Prev Close
$72.40
Open
$70.76
Day's High
$71.29
Day's Low
$70.28
Volume
285,124
Avg. Vol
1,178,707
52-wk High
$75.10
52-wk Low
$50.29

LLY.N

Chart for LLY.N

About

Eli Lilly and Company, discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through facilities in the United States, Puerto Rico, and 15 other countries. Its products are sold... (more)

Overall

Beta: 0.45
Market Cap (Mil.): $80,612.32
Shares Outstanding (Mil.): 1,113.43
Dividend: 0.50
Yield (%): 2.76

Financials

  LLY.N Industry Sector
P/E (TTM): 28.98 37.83 38.47
EPS (TTM): 2.50 -- --
ROI: 10.16 18.99 18.25
ROE: 15.57 19.75 19.13
Search Stocks

Eli Lilly and Adocia agree to develop fast-acting insulin

PARIS - U.S. drugmaker Eli Lilly and French biotech Adocia said on Friday they agreed a worldwide licensing partnership to develop an ultra-rapid insulin to treat patients with Type 1 and Type 2 diabetes.

19 Dec 2014

Eli Lilly and Adocia agree to develop ultra-rapid insulin

PARIS, Dec 19 - U.S. drugmaker Eli Lilly and French biotech Adocia said on Friday they agreed a worldwide licensing partnership to develop ultra-rapid insulin to treat patients with Type 1 and Type 2 diabetes.

19 Dec 2014

Once-weekly Lilly diabetes drug wins EU approval

- The European Commission has granted marketing approval to Eli Lilly and Co's injectable Trulicity treatment for adults with type 2 diabetes, the U.S. drugmaker said on Tuesday.

25 Nov 2014

Once-weekly Lilly diabetes drug wins EU approval

Nov 25 - The European Commission has granted marketing approval to Eli Lilly and Co's injectable Trulicity treatment for adults with type 2 diabetes, the U.S. drugmaker said on Tuesday.

25 Nov 2014

Lilly, Boehringer revise terms of diabetes drugs alliance

- Eli Lilly and Co and German drugmaker Boehringer Ingelheim said they had revised the structure of their diabetes alliance for some countries.

29 Oct 2014

Lilly, Boehringer revise terms of diabetes drugs alliance

Oct 29 - Eli Lilly and Co and German drugmaker Boehringer Ingelheim said they had revised the structure of their diabetes alliance for some countries.

29 Oct 2014

U.S. judge slashes $9 billion award vs Takeda, Lilly over diabetes drug

- A U.S. judge on Monday slashed a $9 billion punitive damages award to $36.8 million against Takeda Pharmaceutical Co and Eli Lilly & Co over their Actos diabetes drug, although she rejected their request for a new trial.

27 Oct 2014

U.S. judge pares $9 bln award against Takeda, Eli Lilly over drug

NEW YORK, Oct 27 - A U.S. judge on Monday slashed a $9 billion punitive damage award against Takeda Pharmaceutical Co and Eli Lilly & Co over their Actos diabetes drug to $36.8 million, according to a court filing.

27 Oct 2014

BRIEF-Virbac to acquire United States veterinary assets from Eli Lilly

* Agrees to acquire veterinary assets from Eli Lilly in United States

27 Oct 2014

Lilly profit plunges as cheaper generics take toll

- Eli Lilly and Co said its quarterly earnings plunged 58 percent, hurt by special charges and generic competition for its Cymbalta depression drug, but it affirmed its full-year profit forecast.

23 Oct 2014

Competitors

  Price Change
Takeda Pharmaceutical Co Ltd (4502.T) ¥5,001 +73.50
Johnson & Johnson (JNJ.N) $106.23 +0.68
Pfizer Inc. (PFE.N) $31.98 +0.04
Novartis AG (NOVN.VX) CHF93.05 +0.95
Merck & Co., Inc. (MRK.N) $58.63 -0.95
Abbott Laboratories (ABT.N) $46.26 +0.21
Sanofi SA (SASY.PA) €75.03 -0.35
AstraZeneca plc (AZN.L) 4,565.00p +22.50
GlaxoSmithKline plc (GSK.L) 1,392.00p +13.50
Bristol-Myers Squibb Co (BMY.N) $60.67 -0.63

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks